Article Information
History
- January 10, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Robert Jirásko1,*,
- Jakub Idkowiak1,
- Denise Wolrab1,
- Aleš Kvasnička2,
- David Friedecký2,
- Krzysztof Polański3,
- Hana Študentová4,
- Vladimír Študent5,
- Bohuslav Melichar4 and
- Michal Holčapek1
- 1Department of Analytical Chemistry, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 53210 Pardubice, Czech Republic
- 2Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University and Department of Clinical Biochemistry, University Hospital Olomouc, 779 00 Olomouc, Czech Republic
- 3Wellcome Sanger Inst, Wellcome Genome Campus, Cambridge, England
- 4Department of Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic
- 5Department of Urology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic
- ↵*Corresponding author: Robert Jirásko, Ph.D., Department of Analytical Chemistry, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 53210 Pardubice, Czech Republic, e-mail: robert.jirasko{at}upce.cz, phone: +420 466 037 089, fax: +420 466 037 068
Posted January 10, 2022.
Altered plasma, urine, and tissue profiles of sulfatides and sphingomyelins in patients with renal cell carcinoma
